470 related articles for article (PubMed ID: 32806517)
1. Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms.
Chatain N; Koschmieder S; Jost E
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806517
[TBL] [Abstract][Full Text] [Related]
2. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
Kaushansky K; Zhan H
Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
[TBL] [Abstract][Full Text] [Related]
3. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
Fisher DAC; Fowles JS; Zhou A; Oh ST
Front Immunol; 2021; 12():683401. PubMed ID: 34140953
[TBL] [Abstract][Full Text] [Related]
5. Disease modifying agents of myeloproliferative neoplasms: a review.
Lee SE
Blood Res; 2021 Apr; 56(S1):S26-S33. PubMed ID: 33935032
[TBL] [Abstract][Full Text] [Related]
6. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
7. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
Liisborg C
Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in understanding myelofibrosis and essential thrombocythemia.
Vainchenker W; Constantinescu SN; Plo I
F1000Res; 2016; 5():. PubMed ID: 27134742
[TBL] [Abstract][Full Text] [Related]
9. [Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review].
He ZP; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):589-594. PubMed ID: 29665937
[TBL] [Abstract][Full Text] [Related]
10. Functional Consequences of Mutations in Myeloproliferative Neoplasms.
Constantinescu SN; Vainchenker W; Levy G; Papadopoulos N
Hemasphere; 2021 Jun; 5(6):e578. PubMed ID: 34095761
[TBL] [Abstract][Full Text] [Related]
11. [Myeloproliferative neoplasms - Update on diagnosis and treatment].
Meyer SC; Drexler B; Skoda RC
Ther Umsch; 2019; 76(9):487-495. PubMed ID: 32157965
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases.
La Spina E; Giallongo S; Giallongo C; Vicario N; Duminuco A; Parenti R; Giuffrida R; Longhitano L; Li Volti G; Cambria D; Di Raimondo F; Musumeci G; Romano A; Palumbo GA; Tibullo D
Front Oncol; 2023; 13():1141610. PubMed ID: 36910610
[TBL] [Abstract][Full Text] [Related]
14. Calreticulin mutations in myeloproliferative neoplasms.
Lavi N
Rambam Maimonides Med J; 2014 Oct; 5(4):e0035. PubMed ID: 25386351
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and myeloproliferative neoplasms.
Lussana F; Rambaldi A
J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
Tefferi A
Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
[TBL] [Abstract][Full Text] [Related]
17. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.
Barosi G; Lupo L; Rosti V
Curr Hematol Malig Rep; 2012 Mar; 7(1):50-6. PubMed ID: 22278747
[TBL] [Abstract][Full Text] [Related]
18. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
Verma T; Papadantonakis N; Peker Barclift D; Zhang L
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339265
[TBL] [Abstract][Full Text] [Related]
19. The Role of Inflammation and Inflammasome in Myeloproliferative Disease.
Longhitano L; Li Volti G; Giallongo C; Spampinato M; Barbagallo I; Di Rosa M; Romano A; Avola R; Tibullo D; Palumbo GA
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32707883
[TBL] [Abstract][Full Text] [Related]
20. Murine Models of Myelofibrosis.
Jacquelin S; Kramer F; Mullally A; Lane SW
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32842500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
